Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial

Annals of Oncology

Volumn 26, Issue 4, 2015, Pages 724-730

  Falcone, A ^a   Salvatore, L ^a   Boni, L ^b   Loupakis, F ^a   Cremolini, C ^a   Fornaro, L ^b   Schirripa, M ^a   Cupini, S ^b   Barbara, C ^b   Safina, V ^b   Granetto, C ^c   Fea, E ^c   Antonuzzo, L ^d   Boni, C ^e   Allegrini, G ^b   Chiara, S ^f   Amoroso, D ^b   Bonetti, A ^g  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g Ospedale Mater Salutis   (Italy)

Author keywords

Bevacizumab; Beyond progression; Metastatic colorectal cancer; Second line

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE COURSE; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RETREATMENT; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETREATMENT; SURVIVAL RATE;

EID: 84926476833     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv012     Document Type: Article

References (13)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
3. Tebbutt NC, Wilson K, Gebski VJ et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198.
4. Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14(11): 1077-85.
5. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
6. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-410.
7. Bagri A, Berry L, Gunter B et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010; 16(15):3887-3900.
8. Grothey A, Sugrue MM, Purdie DM et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26:5326-5334.
9. Cohn AL, Bekaii-Saab T, Bendell JC et al. Clinical outcomes in bevacizumab (BV)- treated patients ( pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). Proc Am Soc Clin Oncol 2010; 28(suppl): abstr 3596.
10. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14(1): 29-37.
11. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatinbased regimen. J Clin Oncol 2012; 30: 3499-3506.
12. Tabernero J, Van Cutsem E, Lakomý R et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. Eur J Cancer 2014; 50(2): 320-331.
13. Grothey A, Van Cutsem E, Sobrero A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312.